3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
1905
Breast Neoplasms
1425
Carcinoma, Non-Small-Cell Lung
1178
Prostatic Neoplasms
740
Colorectal Neoplasms
686
Neoplasm Metastasis
623
Multiple Myeloma
548
Melanoma
529
Ovarian Neoplasms
456
Lung Neoplasms
447
Lymphoma, Non-Hodgkin
385
Lymphoma
374
Recurrence
373
Leukemia, Myeloid, Acute
370
Pancreatic Neoplasms
358
Carcinoma, Renal Cell
339
Carcinoma, Hepatocellular
286
Stomach Neoplasms
281
Leukemia, Lymphocytic, Chronic, B-Cell
268
Lymphoma, Follicular
254
Head and Neck Neoplasms
246
Glioblastoma
220
Leukemia
215
Small Cell Lung Carcinoma
183
Lymphoma, Large B-Cell, Diffuse
183
Squamous Cell Carcinoma of Head and Neck
181
Urinary Bladder Neoplasms
175
Carcinoma
175
Uterine Cervical Neoplasms
174
Advanced Solid Tumors
161
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
Diffuse Large B-Cell Lymphoma Refractory
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA